Candel Therapeutics (CADL) said Wednesday it released final survival data from its phase 2a trial of CAN-2409 in advanced non-small cell lung cancer patients resistant to immune checkpoint inhibitor treatment.
The study demonstrated positive results, with a median overall survival of 24.5 months in the evaluable patients, surpassing standard care outcomes.
Key findings include a median overall survival of 21.5 months in patients with progressive disease despite ICI therapy, compared to 9.8 to 11.8 months with standard docetaxel chemotherapy. Additionally, 37% of patients survived beyond two years after receiving CAN-2409, while 69% showed regression in uninjected tumors, demonstrating an abscopal effect. Non-squamous NSCLC patients had the best outcomes, with a median overall survival of 25.4 months, the company said.
Throughout the long-term study, CAN-2409 maintained a strong safety profile and was well-tolerated by patients, Candel Therapeutics said.
Candel shares rose 2.5% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.